AccessibilityHelpAbout Us
BioSyent logo

BioSyent(OTC) BIOYF

Market Cap$128.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)+2,154%
5 Year+107%
1 Year+32%
1 Month+4%
$11.25
-1.32%
-0.15Today
BioSyent last closing stock price
MetricPriceDate
Last closeUSD 11.252026-09-18
BioSyent stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.46%USD 11.302026-09-11
1 month+3.83%USD 10.842026-08-19
3 month+14.22%USD 9.852026-06-18
Year to date+19.47%USD 9.422025-12-30
1 year+31.64%USD 8.552025-09-18
3 year+99.13%USD 5.652023-09-19
5 year+106.85%USD 5.442021-09-17
Since inception+2,153.91%USD 0.512012-06-01

BioSyent Financials at a Glance

Market Cap

$128.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$55.71M

Net Income (TTM)

CA$9.87M

EPS (TTM)

$0.62

P/E Ratio

18.06

Dividend

$0.16

Beta (Volatility)

0.20 (Low)

Price

$11.25

Volume

3,188

Open

$11.24

Previous Close

$11.25

Daily Range

$11.24 - $11.25

52-Week Range

$7.63 - $12.00

Estimated Earnings Date

Nov 19, 2026

BIOYF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioSyent

BioSyent Inc. is a Canadian pharmaceutical company focused on acquiring, developing, and selling healthcare products. The company operates both domestically and internationally, offering a diverse range of products aimed at addressing various medical needs.

Products and Services
  • FeraMAX Pd Therapeutic 150 for iron deficiency anemia
  • Tibella, a hormone replacement therapy
  • Inofolic, addressing polycystic ovarian syndrome symptoms
Growth Outlook
  • Recent quarterly revenue reached CAD 19.88 million, a significant increase
  • Trailing twelve months (TTM) revenue shows a strong upward trend
  • Market expansion opportunities in international markets are promising
Financial Highlights
  • Net income for the latest quarter was CAD 2.85 million
  • TTM gross profit margin stands at 70.2%, indicating strong profitability
  • Current ratio of 2.07 suggests solid liquidity position
BioSyent Inc. has established itself as a key player in the pharmaceutical industry, with a focus on innovative healthcare solutions. The company's product portfolio includes treatments for iron deficiency anemia, hormone replacement therapies, and natural health products, catering to a wide range of medical conditions. The growth outlook for BioSyent is robust, supported by recent revenue increases and a strong TTM performance. The company is well-positioned to capitalize on market expansion opportunities, particularly in international markets, which could further enhance its revenue streams. Financially, BioSyent demonstrates a solid performance with a net income of CAD 2.85 million in the latest quarter and a gross profit margin of 70.2%. The current ratio of 2.07 indicates a strong liquidity position, allowing the company to meet its short-term obligations effectively. Overall, BioSyent Inc. presents a compelling opportunity for investors interested in the pharmaceutical sector.
AI Generated • Aug 28, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

61

CEO

René C. Goehrum

Website

www.biosyent.com

Headquarters

Mississauga, ON L5N 6M1, CA

BIOYF Financials

Key Financial Metrics (TTM)

Gross Margin

70.21%

Operating Margin

23.21%

Net Income Margin

17.73%

Return on Equity

22.92%

Return on Capital

26.74%

Return on Assets

16.32%

Earnings Yield

5.54%

Dividend Yield

1.37%

Payout Ratio

24.01%

Stock Overview

Market Cap

$128.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

11.31M

Volume

3.19K

Avg. Volume

2.71K

Financials (TTM)

Gross Profit

CA$39.11M

Operating Income

CA$12.93M

EBITDA

CA$15.13M

Operating Cash Flow

CA$12.10M

Capital Expenditure

-CA$298.71K

Free Cash Flow

CA$11.80M

Cash & ST Invst.

CA$8.95M

Total Debt

CA$3.14M

BioSyent Performance Analysis

BioSyent annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 21,450,330-6.0%
20232023-12-31CAD 23,405,6519.1%
20242024-12-31CAD 25,570,7159.3%
20252025-12-31CAD 30,811,08920.5%
BioSyent sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3020.1%
Q42025-12-31-20.9%
Q12026-03-3144.3%
Q22026-06-3042.6%
BioSyent annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD 0.33-14.1%
20232023-12-31CAD 0.3917.6%
20242024-12-31CAD 0.4514.3%
20252025-12-31CAD 0.5624.7%
BioSyent sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3027.8%
Q42025-12-31-21.7%
Q12026-03-3111.1%
Q22026-06-3025.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$19.88M

+95.3%

Gross Profit

CA$12.93M

+63.4%

Gross Margin

65.02%

N/A

Market Cap

$128.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$181.32K

N/A

Employees

711

N/A

Net Income

CA$2.85M

+41.3%

EBITDA

CA$4.98M

+67.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$8.95M

-56.1%

Total Debt

CA$3.14M

+233.5%

Accounts Receivable

CA$6.77M

+37.6%

Inventory

CA$10.75M

+121.1%

Long Term Debt

CA$699.07K

-4.9%

Short Term Debt

CA$2.44M

+1079.7%

Return on Assets

16.32%

N/A

Return on Invested Capital

27.70%

N/A

Free Cash Flow

CA$2.54M

-26.0%

Operating Cash Flow

CA$2.55M

-26.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LOVFFCannara Biotech Inc.
$1.43-0.14%
GRUSFGrown Rogue International Inc.
$0.42-2.74%
PLNHPlanet 13 Holdings Inc.
$0.13-3.37%
ETSTEarth Science Tech, Inc.
$0.09-1.22%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$152.71-1.36%
NVDANvidia
$222.27+1.34%
AGNCAGNC Investment Corp.
$9.87-0.40%
INTCIntel
$108.60-0.18%

Questions About BIOYF

What is the current price of BioSyent?

BioSyent is trading at $11.25 per share.

What is the 52-week range for BioSyent?

Over the past 52 weeks, BioSyent has traded between $7.63 and $12.00.

How much debt does BioSyent have?

As of the most recent reporting period, BioSyent reported total debt of CA$2.21M.

How much cash does BioSyent have on hand?

BioSyent reported CA$3.65M in cash and cash equivalents in its most recent financial results.

What is BioSyent’s dividend yield?

BioSyent currently has a dividend yield of 1.37%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services